Moderna Turns a Profit as R&D Spending Falls: Rapid Earnings Reaction
The Motley Fool ·
Key points
- In Q3, Moderna earned $162 million, reversing a $200 million loss from the same period last year, as peak vaccine season overlapped with lower R&D outlays.
- Nine-month results still show a net loss of about $2 billion, indicating that the quarterly profit does not reflect ongoing profitability.
- Sales gains came from international vaccine deliveries under long-term government contracts, rather than a surge in base business demand.
- Research costs declined because late-stage infectious-disease trials wound down, contributing more to the quarterly profit than incremental sales did.
- The company issued about $2.6 billion in convertible notes in September, with capped calls to limit dilution from potential share conversion.
- Moderna’s long-term trajectory remains tied to COVID vaccine revenue, though upside could come from intismeran, a cancer vaccine developed with Merck, which showed significant melanoma risk reduction in a Phase 3 trial.
- Investors are watching for regulatory filing of intismeran and for pivotal data on propionic acidemia expected in 2026, which could alter the growth outlook.
Summary
Moderna swung to a Q3 profit of $162 million largely as research spending fell after winding down late-stage trials, offsetting a peak-season sales boost from fall COVID vaccines. The earnings improvement occurred despite nine-month losses totaling around $2 billion, with much of the cash outlook driven by $2.6 billion from convertible notes rather than core business gains. Long-term revenue remains tied to COVID vaccines, while potential upside hinges on new programs like intismeran with Merck, which showed a 42% risk reduction in a melanoma trial. Regulators could see updates on intismeran, and pivotal data for propionic acidemia is anticipated in 2026, shaping the roadmap ahead.
This summary was written with AI. The full story has every detail.